Product Program year 2025 Source: CMS Open Payments

Blujepa

Drug Anti-Infective

NDC 0173-0922-45

Open in the dashboard

General payments

$16,228

194 payments

Research payments

$0

0 payments

Through program year 2025, $16,228 in general payments and $0 in research payments were reported against Blujepa (Anti-Infective).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $16,228 194

Breakdown

Who paid General payments · program year 2025
  1. GlaxoSmithKline, LLC. $16,228 194 payments
Top recipients General payments · program year 2025
  1. Xolani Mdluli Infectious Disease · Palm Springs, CA $313 2% · 4 payments
  2. John Aldrich Alejandro Nurse Practitioner, Family · Irvine, CA $299 2% · 3 payments
  3. Itunu Oluwa Arojo Urology · Sugar Land, TX $182 1% · 2 payments
  4. Joseph Erwin Salunday Nurse Practitioner, Family · Orange, CA $174 1% · 2 payments
  5. John Oreilly Infectious Disease · Las Vegas, NV $161 <1% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nurse Practitioner, Family Nurse Practitioner $7,662 48% · 74 practitioners
  2. Physician Assistant $1,929 12% · 22 practitioners
  3. Infectious Disease Internal Medicine $1,203 7% · 15 practitioners
  4. Nurse Practitioner $725 4% · 9 practitioners
  5. Urology $606 4% · 5 practitioners

The top 5 of 23 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $5,736 35% · 56 recipients
  2. California $2,037 13% · 18 recipients
  3. Alabama $1,881 12% · 17 recipients
  4. Massachusetts $1,854 11% · 17 recipients
  5. Florida $957 6% · 17 recipients

The top 5 of 21 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

194 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record